<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385097</url>
  </required_header>
  <id_info>
    <org_study_id>CHL.2/01-2014/M</org_study_id>
    <nct_id>NCT02385097</nct_id>
  </id_info>
  <brief_title>Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block</brief_title>
  <official_title>A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sintetica SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sintetica SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference&#xD;
      product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for&#xD;
      distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without&#xD;
      any supplementation in the first 45 min.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference&#xD;
      product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for&#xD;
      distal upper limb surgeries, without any supplementation in the first 45 min (see definitions&#xD;
      below), calculated from the time of readiness for surgery (complete sensory block).&#xD;
      Successful block: anaesthesia adequate for the surgery (complete sensory block), without any&#xD;
      supplementation in the first 45 min (even if surgery lasts for &gt; 45 min), calculated from the&#xD;
      time of readiness for surgery (complete sensory block). Supplementation: i.v. premedication&#xD;
      or general anaesthesia or pre- or intra-operative systemic analgesia or additional local&#xD;
      anaesthetic infiltration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Successful Block for Distal Upper Limb Surgeries</measure>
    <time_frame>45 min from the time of readiness of surgery</time_frame>
    <description>Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)</measure>
    <time_frame>Up to 1 h after last perineural injection</time_frame>
    <description>Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Motor Block</measure>
    <time_frame>Up to 1 h after last perineural injection</time_frame>
    <description>Time period from completion of the final perineural injection (time 0 h) to achievement of motor block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Regression of Sensory Block</measure>
    <time_frame>Up to 12 hrs after surgery</time_frame>
    <description>Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Regression of Motor Block</measure>
    <time_frame>Up to 12 hrs after surgery</time_frame>
    <description>Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partecipants Received Rescue Anaesthesia or Rescue Analgesia</measure>
    <time_frame>45 min from the time of readiness of surgery</time_frame>
    <description>partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Received Post-operative Analgesia</measure>
    <time_frame>From surgery day to 24 hrs post surgery</time_frame>
    <description>Number of subjects who received the first post-operative analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Eligibility for Home Discharge</measure>
    <time_frame>from surgery day to 24h post surgery</time_frame>
    <description>Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>from surgery day to day 6 +/- 1 after surgery</time_frame>
    <description>Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Symptoms</measure>
    <time_frame>from surgery day to day 6 +/- 1 after surgery</time_frame>
    <description>Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>from surgery day to 24 hrs post surgery</time_frame>
    <description>The following normal ranges Heart Rate parameters will be used:&#xD;
50-90 beats/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>from surgery day to 24 hrs post surgery</time_frame>
    <description>The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:&#xD;
Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>from surgery day to 24 hrs post surgery</time_frame>
    <description>The following normal ranges SpO2 parameters will be used:&#xD;
Peripheral Oxygen Saturation: ≥ 95%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Normal Electrocardiogram (ECG) Parameters</measure>
    <time_frame>from surgery day to 24 hrs post surgery</time_frame>
    <description>Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used:&#xD;
Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Axillary Nerve Block</condition>
  <arm_group>
    <arm_group_label>Chloroprocaine HCl 2% (20 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine 0.75% (7.5 mg/mL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroprocaine HCl 2%</intervention_name>
    <description>Single Administration (20mL) by Axillary Nerve Route</description>
    <arm_group_label>Chloroprocaine HCl 2% (20 mg/mL)</arm_group_label>
    <other_name>Ampres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.75%</intervention_name>
    <description>Single Administration (20mL) by Axillary Nerve Route</description>
    <arm_group_label>Ropivacaine 0.75% (7.5 mg/mL)</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sex and surgery: male and female patients scheduled for short duration (&lt; 60 min)&#xD;
             distal upper limb surgery under axillary nerve block anaesthesia&#xD;
&#xD;
          2. Age: ≥ 18 years old&#xD;
&#xD;
          3. Body Mass Index (BMI): 18 - 32 kg/m2 inclusive&#xD;
&#xD;
          4. ASA physical status: I-III&#xD;
&#xD;
          5. Informed consent: signed written informed consent before inclusion in the study&#xD;
&#xD;
          6. Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; ability to co-operate with the investigator&#xD;
             and to comply with the requirements of the entire study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical findings: clinically significant abnormal physical findings which could&#xD;
             interfere with the objectives of the study. Contraindications to peripheral nerve&#xD;
             block anaesthesia. History of neuromuscular diseases to the upper extremities&#xD;
&#xD;
          2. Axillary status: Axillary local infections, surgical scarring and pathological lymph&#xD;
             node enlargement&#xD;
&#xD;
          3. ASA physical status: IV-V&#xD;
&#xD;
          4. Further anaesthesia: Patients anticipated to be requiring further anaesthesia (general&#xD;
             or local anaesthesia)&#xD;
&#xD;
          5. Chronic pain syndromes: Patients with chronic pain syndromes (taking opioids,&#xD;
             antidepressants, anticonvulsant agents)&#xD;
&#xD;
          6. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or&#xD;
             formulations ingredients; ascertained or presumptive hypersensitivity to the amide and&#xD;
             ester-type anaesthetics&#xD;
&#xD;
          7. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular,&#xD;
             respiratory, skin, haematological, endocrine or neurological diseases that may&#xD;
             interfere with the aim of the study; ascertained psychiatric diseases, sepsis, blood&#xD;
             coagulation disorders, insulin dependent diabetes mellitus, terminal kidney failure&#xD;
&#xD;
          8. Medications: Medication known to interfere with the extent of regional blocks (see&#xD;
             chloroprocaine and ropivacaine SmPCs) for 2 weeks before the start of the study.&#xD;
             Hormonal contraceptives for females will be allowed&#xD;
&#xD;
          9. Investigative drug studies: participation in the evaluation of any investigational&#xD;
             product for 3 months before this study, calculated from the first day of the month&#xD;
             following the last visit of the previous study&#xD;
&#xD;
         10. Drug, alcohol: history of drug or alcohol abuse&#xD;
&#xD;
         11. Pregnancy: missing or positive pregnancy test at screening, pregnant or lactating&#xD;
             women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Kimberger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of General Anesthesia and Intensive Care Medicine, Spitalgasse 23, 1090 Vienna, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Camponovo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology,Clinica Ars Medica,Via Cantonale, CH-6929 Gravesano, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Saporito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiology, Ospedale Regionale di Bellinzona, CH-6500 Bellinzona, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Claudio Camponovo</name>
      <address>
        <city>Gravesano</city>
        <state>Lugano</state>
        <zip>CH-6929</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <results_first_submitted>April 29, 2021</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 17, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02385097/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From April 2015 to May 2017 in Medical clinic and Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
          <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
        </group>
        <group group_id="P2">
          <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
          <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>211 patients were enrolled in the study. 106 of the enrolled patients were randomised to the Test treatment group and 105 patients to the Reference treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
          <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
        </group>
        <group group_id="B2">
          <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
          <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="15.4"/>
                    <measurement group_id="B2" value="52.6" spread="18.7"/>
                    <measurement group_id="B3" value="54" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.58" spread="3.83"/>
                    <measurement group_id="B2" value="25.61" spread="3.55"/>
                    <measurement group_id="B3" value="25.60" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Successful Block for Distal Upper Limb Surgeries</title>
        <description>Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).</description>
        <time_frame>45 min from the time of readiness of surgery</time_frame>
        <population>211 patients were enrolled in the study. 106 of the enrolled patients were randomised to the Test treatment group and 105 patients to the Reference treatment group. Two subjects, one in the Test and one in the Reference treatment group discontinued the study before treatment (withdrawal by subject). In the Test treatment group, 105 patients were treated and completed the study. In the Reference treatment group, 104 patients were treated, 103 of them completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Successful Block for Distal Upper Limb Surgeries</title>
          <description>Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).</description>
          <population>211 patients were enrolled in the study. 106 of the enrolled patients were randomised to the Test treatment group and 105 patients to the Reference treatment group. Two subjects, one in the Test and one in the Reference treatment group discontinued the study before treatment (withdrawal by subject). In the Test treatment group, 105 patients were treated and completed the study. In the Reference treatment group, 104 patients were treated, 103 of them completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)</title>
        <description>Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories</description>
        <time_frame>Up to 1 h after last perineural injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)</title>
          <description>Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Motor Block</title>
        <description>Time period from completion of the final perineural injection (time 0 h) to achievement of motor block</description>
        <time_frame>Up to 1 h after last perineural injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Motor Block</title>
          <description>Time period from completion of the final perineural injection (time 0 h) to achievement of motor block</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Regression of Sensory Block</title>
        <description>Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory</description>
        <time_frame>Up to 12 hrs after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Regression of Sensory Block</title>
          <description>Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="64" upper_limit="75"/>
                    <measurement group_id="O2" value="451" lower_limit="413" upper_limit="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Regression of Motor Block</title>
        <description>Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)</description>
        <time_frame>Up to 12 hrs after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Regression of Motor Block</title>
          <description>Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="60" upper_limit="69"/>
                    <measurement group_id="O2" value="415" lower_limit="388" upper_limit="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partecipants Received Rescue Anaesthesia or Rescue Analgesia</title>
        <description>partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)</description>
        <time_frame>45 min from the time of readiness of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Partecipants Received Rescue Anaesthesia or Rescue Analgesia</title>
          <description>partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Received Post-operative Analgesia</title>
        <description>Number of subjects who received the first post-operative analgesia</description>
        <time_frame>From surgery day to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Received Post-operative Analgesia</title>
          <description>Number of subjects who received the first post-operative analgesia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Eligibility for Home Discharge</title>
        <description>Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time</description>
        <time_frame>from surgery day to 24h post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Eligibility for Home Discharge</title>
          <description>Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161" lower_limit="155" upper_limit="170"/>
                    <measurement group_id="O2" value="355.5" lower_limit="260" upper_limit="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP</description>
        <time_frame>from surgery day to day 6 +/- 1 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Symptoms</title>
        <description>Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)</description>
        <time_frame>from surgery day to day 6 +/- 1 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Symptoms</title>
          <description>Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>burning : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>burning : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tingling : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tingling : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pins and needles sensation : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pins and needles sensation : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pricking : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pricking : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aching : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aching : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>numbness : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>numbness : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypoesthesia : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypoesthesia : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain surgery site : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain surgery site : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diffuse hair loss : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diffuse hair loss : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>itching : discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>itching : day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>The following normal ranges Heart Rate parameters will be used:&#xD;
50-90 beats/min</description>
        <time_frame>from surgery day to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>The following normal ranges Heart Rate parameters will be used:&#xD;
50-90 beats/min</description>
          <units>beats/minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="12"/>
                    <measurement group_id="O2" value="73.6" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="10.8"/>
                    <measurement group_id="O2" value="71.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="11.5"/>
                    <measurement group_id="O2" value="73" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:&#xD;
Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg</description>
        <time_frame>from surgery day to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:&#xD;
Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="20.5"/>
                    <measurement group_id="O2" value="136.2" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.6" spread="18.9"/>
                    <measurement group_id="O2" value="138" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure at discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.5" spread="17.8"/>
                    <measurement group_id="O2" value="130.1" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" spread="11.4"/>
                    <measurement group_id="O2" value="80.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="10.7"/>
                    <measurement group_id="O2" value="80.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure at discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="11.1"/>
                    <measurement group_id="O2" value="75.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2</title>
        <description>The following normal ranges SpO2 parameters will be used:&#xD;
Peripheral Oxygen Saturation: ≥ 95%</description>
        <time_frame>from surgery day to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2</title>
          <description>The following normal ranges SpO2 parameters will be used:&#xD;
Peripheral Oxygen Saturation: ≥ 95%</description>
          <units>percentage of SpO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.05" spread="1.51"/>
                    <measurement group_id="O2" value="97.36" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.47" spread="1.52"/>
                    <measurement group_id="O2" value="97.61" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Normal Electrocardiogram (ECG) Parameters</title>
        <description>Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used:&#xD;
Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec</description>
        <time_frame>from surgery day to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
            <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
            <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Normal Electrocardiogram (ECG) Parameters</title>
          <description>Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used:&#xD;
Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chloroprocaine HCl 2% (20 mg/mL)</title>
          <description>Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Chloroprocaine HCl 2%: Single Administration (20mL) by Axillary Nerve Route</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaine 0.75% (7.5 mg/mL)</title>
          <description>Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL&#xD;
Ropivacaine 0.75%: Single Administration (20mL) by Axillary Nerve Route</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="50" subjects_affected="48" subjects_at_risk="106"/>
                <counts group_id="E2" events="43" subjects_affected="41" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaestesia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Paraestesia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E2" events="40" subjects_affected="28" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>burning sensation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>sensorimotor disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Elisabetta Donati, Corporate Director Scientific Affairs</name_or_title>
      <organization>Sintetica SA</organization>
      <phone>+41.91.640.42.50</phone>
      <email>edonati@sintetica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

